Gossamer Bio Faces Securities Lawsuits Over Failed PROSERA Study
Analysis based on 59 articles · First reported Apr 01, 2026 · Last updated Apr 15, 2026
The market is negatively impacted by the significant drop in Gossamer Bio's stock price, reflecting investor distrust due to alleged misleading statements. This event highlights the risks associated with clinical trial outcomes and corporate transparency in the biotechnology sector.
Multiple law firms, including Bronstein, Gewirtz & Grossman, Pomerantz LLP, The Schall Law Firm, Faruqi & Faruqi, Law Offices of Howard G. Smith, and Glancy Prongay & Rotter, have filed class action lawsuits against Gossamer Bio. The lawsuits allege that Gossamer Bio made materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension. Specifically, the company is accused of concealing adverse facts about the study's design, including a failure to adequately control for placebo response at Latin American testing sites. On February 23, 2026, Gossamer Bio announced that the study failed to meet its primary endpoint, leading to an over 80% drop in its stock price. Investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of June 1, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard